Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Bjoern Bornkamp"'
Autor:
Kapildeb Sen, Frank Bretz, Evgeny Degtyarev, Yiyun Zhang, Bjoern Bornkamp, Lisa V. Hampson, David Lebwohl, Mouna Akacha, Antonella Maniero, Emmanuel Zuber
Publikováno v:
JCO precision oncology. 3
The diversity of patient journeys can raise fundamental questions regarding the evaluation of drug effects in clinical trials to inform clinical practice. When defining the treatment effect of interest in a trial, the researcher needs to account for
Publikováno v:
Statistics in Biosciences. 10:283-296
One of the main goals of modern drug development is customized care, where doctors match the right patient to the right treatment at the right dose, based on quantitative evidence. In this paper we review three key aspects of drug development that ar
Autor:
Nicholas H. G. Holford, Joseph F. Standing, Flora T. Musuamba, Norbert Benda, Andrew C. Hooker, Solange Corriol-Rohou, Frank Bretz, P H van der Graaf, Falk Ehmann, Martin Posch, I. Skottheim Rusten, S. Y. A. Cheung, Bjoern Bornkamp, Lena E. Friberg, Kristin E. Karlsson, James W.T. Yates, Robert Hemmings, A. Brochot, Efthymios Manolis, Neal Thomas, Susan Cole, Shampa Das, F. Serone, Valeria Gigante, Scott Berry, Thomas Dumortier, Justin L. Hay, Kayode Ogungbenro
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:418-429
Inadequate dose selection for confirmatory trials is currently still one of the most challenging issues in drug development, as illustrated by high rates of late-stage attritions in clinical development and postmarketing commitments required by regul
Autor:
Thomas Jaki, Allan Gordon, Pamela Forster, Luc Bijnens, Bjoern Bornkamp, Werner Brannath, Roberto Fontana, Mauro Gasparini, Lisa V. Hampson, Tom Jacobs, Byron Jones, Xavier Paoletti, Martin Posch, Andrew Titman, Richardus Vonk, Franz Koenig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd4bc10bac78ce30f87f5533370374d
https://doi.org/10.1002/pst.1942
https://doi.org/10.1002/pst.1942
Publikováno v:
Pharmaceutical Statistics. 14:359-367
Understanding the dose-response relationship is a key objective in Phase II clinical development. Yet, designing a dose-ranging trial is a challenging task, as it requires identifying the therapeutic window and the shape of the dose-response curve fo
Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials gives a thorough presentation of state-of-the-art methods for early phase clinical trials. The methodology of clinical trials has advanced greatly over the last 20 years
Autor:
Lisa V. Hampson, A Gordon, Byron Jones, Roberto Fontana, Martin Posch, Richardus Vonk, Franz Koenig, Xavier Paoletti, Pamela Suzanne Forster, Thomas Jaki, Andrew Titman, Bjoern Bornkamp, Luc Bijnens, Tom Jacobs, Mauro Gasparini, Werner Brannath
Publikováno v:
Pharmaceutical Statistics
This paper provides an overview of “Improving Design, Evaluation and Analysis of early drug development Studies” (IDEAS), a European Commission–funded network bringing together leading academic institutions and small‐ to large‐sized pharmac